View Older Stories View More Recent Stories

Dec 4, 2017 08:06AM BioTime (BTX) Presented Detailed Data on Successful Pivotal Trial of Renevia in Euripe
Dec 4, 2017 08:00AM Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference
Dec 4, 2017 07:00AM AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering & Regenerative Medi
Nov 30, 2017 07:00AM Data from BioTime’s Renevia® Program to Be Presented at IFATS Conference
Nov 15, 2017 08:01AM BioTime (BTX) Announces Updated OpRegen® Phase I/IIa Trial Data
Nov 15, 2017 08:00AM BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO
Nov 13, 2017 07:00AM BioTime to Participate in Upcoming Conferences
Nov 9, 2017 04:05PM BioTime Reports Third Quarter Results and Recent Corporate Accomplishments
Nov 8, 2017 07:00AM AgeX Therapeutics VP of New Technology Discovery Aubrey de Grey to Serve on Aging & Longevity Panel at FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London
Nov 2, 2017 12:00AM BioTime to Participate in the Jefferies 2017 London Healthcare Conference
Oct 26, 2017 07:00AM AgeX Therapeutics CEO Michael D. West to Give Special Interview for The Economist’s Conference “The Business of Longevity: Health Innovation for an Ageing World” October 27 in Hong Kong
Oct 24, 2017 07:00AM BioTime to Announce Third Quarter 2017 Results on November 9, 2017
Oct 11, 2017 08:00AM BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit
Oct 11, 2017 07:06AM BioTime (BTX), Processa Enter into HyStem Sublicense for Drug Delivery
Oct 11, 2017 07:00AM BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery
Oct 3, 2017 07:00AM BioTime to Present at the Cell and Gene Meeting on the Mesa
Sep 26, 2017 07:03AM BioTime (BTX) Reports Positive Secondary and Additional Positive Long-Term Data from the Renevia Pivotal Trial
Sep 26, 2017 07:00AM BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia® Pivotal Trial
Sep 25, 2017 07:00AM BioTime Board of Directors Approves Distribution of AgeX Therapeutics Shares to BioTime Shareholders
Sep 21, 2017 07:00AM AgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum
Sep 21, 2017 07:00AM BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum
Sep 20, 2017 07:00AM BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Sep 20, 2017 07:00AM BioTime to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 18, 2017 07:02AM BioTime (BTX) Secures Grant Up to $1.56M from National Institute of Health
Sep 18, 2017 07:00AM BioTime Awarded Grant from the NIH
Sep 14, 2017 05:44PM BioTime (BTX) Says Two Key Patents Providing Protection to OpRegen Remain Upheld
Sep 14, 2017 05:43PM Two Key BioTime Patents Providing Protection to OpRegen® Remain Upheld
Sep 8, 2017 07:00AM BioTime to Present at the Rodman & Renshaw Annual Global Investment Conference
Sep 5, 2017 07:00AM BioTime to Present at the LD Micro San Francisco Summit
Aug 28, 2017 07:00AM BioTime to Present Data at the Military Health System Research Symposium
Aug 17, 2017 07:00AM AgeX Therapeutics Closes $10 Million Capital Raise
Aug 14, 2017 07:00AM BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
Aug 9, 2017 07:00AM AgeX Therapeutics CEO Michael D. West, Ph.D. to Deliver Keynote Address on Biotechnology and Aging at RAAD Festival
Aug 2, 2017 04:10PM BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
Aug 2, 2017 08:42AM BioTime (BTX) Announces AgeX Therapeutics Obtained $10M in Capital
Aug 2, 2017 08:30AM AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations
Jul 25, 2017 04:45PM BioTime (BTX) Granted DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD
Jul 25, 2017 04:30PM BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US
Jul 20, 2017 07:00AM BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
Jul 19, 2017 07:00AM Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting
Jul 18, 2017 07:00AM BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City
Jul 13, 2017 07:00AM BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery
Jun 19, 2017 07:00AM Biotime Expands & Advances Ophthalmology Portfolio
Jun 14, 2017 07:02AM BioTime (BTX) Announces Renevia Achieves Primary Endpoint in European Pivotal Trial
Jun 14, 2017 07:00AM BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial
Jun 8, 2017 04:13PM BioTime (BTX) to Announce Top Line Data From Renevia European Pivotal Trial Next Week
Jun 8, 2017 04:10PM BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial
May 23, 2017 04:30PM BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
May 23, 2017 07:00AM BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
May 11, 2017 07:23AM BioTime (BTX) Presents Retinal Restoration Data at ARVO
View More Recent Stories View Older Stories